Literature DB >> 12036350

Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity.

Angeles Dios1, Robert A Mitchell, Bayan Aljabari, Jodi Lubetsky, KerryAnn O'Connor, Hong Liao, Peter D Senter, Kirk R Manogue, Elias Lolis, Christine Metz, Richard Bucala, David J E Callaway, Yousef Al-Abed.   

Abstract

The pro-inflammatory mediator macrophage migration inhibitory factor (MIF) is produced by immune and endocrine cells and inhibits the antiinflammatory activities of glucocorticoids. MIF also catalyzes the tautomerization of the non-naturally occurring D-isomer of dopachrome, phenylpyruvate, and certain catecholamines, suggesting that MIF might exert its biological effects via enzymatic action on a substrate. However, no physiologically relevant substrate for MIF has been identified. Site-directed mutagenesis studies have not consistently supported a requirement for an intact, functional catalytic site as a prerequisite for MIF bioactivity. We hypothesized that the catalytically active site, but not the enzymatic activity per se, nevertheless plays a critical role in MIF pro-inflammatory activity. Accordingly, we designed small druglike molecules that bind at the catalytically active tautomerase site of MIF and tested the complex for MIF bioactivity. We describe herein the rational design and synthesis of a class of imine conjugates produced by coupling amino acids to a range of benzaldehyde derivatives that inhibit MIF tautomerase and biological activities. We found that aromatic amino acid Schiff bases were better inhibitors of MIF enzymatic and bioactivities compared to the aliphatic ones. For instance, the IC(50) inhibition of MIF tautomerase activity by aromatic amino acid Schiff base methyl esters was achieved at a concentration between 1.65 and 50 microM, suggesting a critical role for the additional binding of the aromatic residues within the vicinity of the active site. The most potent inhibitor of MIF tautomerase activity was 2-[(4-hydroxybenzylidene)amino]-3-(1H-indol-3-yl)propionic acid methyl ester (8), with an IC(50) of 1.65 microM. We found that compound 8 binding to MIF active site resulted in the inhibition of MIF bioactivity in three established bioassays: ERK-1/2 MAP kinase activation, p53-dependent apoptosis, and proliferation of serum-starved cells. Compound 8 inhibited MIF interaction with its as yet unidentified cognate cell surface receptor as shown by flow cytometry, concluding a critical role for the tautomerase active site in receptor binding. Thus the inhibitory effect of compound 8 on MIF bioactivities strongly correlated with the inhibition of MIF tautomerase activity, a connection not made previously through use of small-molecule MIF inhibitors. The inhibitory activity of amino acid-benzaldehyde Schiff base-type MIF antagonists is the first step toward a meaningful structure/function analysis of inhibitors of MIF cellular bioactivities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036350     DOI: 10.1021/jm010534q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

1.  TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner.

Authors:  Inbal Binsky; Frida Lantner; Valentin Grabovsky; Nurit Harpaz; Lev Shvidel; Alain Berrebi; David M Goldenberg; Lin Leng; Richard Bucala; Ronen Alon; Michal Haran; Idit Shachar
Journal:  J Immunol       Date:  2010-03-31       Impact factor: 5.422

2.  Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Authors:  Amanda Sparkes; Patrick De Baetselier; Lea Brys; Inês Cabrito; Yann G-J Sterckx; Steve Schoonooghe; Serge Muyldermans; Geert Raes; Richard Bucala; Peter Vanlandschoot; Jo A Van Ginderachter; Benoît Stijlemans
Journal:  FASEB J       Date:  2018-01-25       Impact factor: 5.191

3.  CD84 is a survival receptor for CLL cells.

Authors:  I Binsky-Ehrenreich; A Marom; M C Sobotta; L Shvidel; A Berrebi; I Hazan-Halevy; S Kay; A Aloshin; I Sagi; D M Goldenberg; L Leng; R Bucala; Y Herishanu; M Haran; I Shachar
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

Review 4.  Midkine as a regulator of B cell survival in health and disease.

Authors:  Sivan Cohen; Idit Shachar
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.

Authors:  Joshua Bloom; Christine Metz; Saisha Nalawade; Julian Casabar; Kai Fan Cheng; Mingzhu He; Barbara Sherry; Thomas Coleman; Thomas Forsthuber; Yousef Al-Abed
Journal:  J Biol Chem       Date:  2016-10-28       Impact factor: 5.157

6.  Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; William L Jorgensen
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

Review 7.  Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation.

Authors:  Beatriz E Rendon; Sharon S Willer; Wayne Zundel; Robert A Mitchell
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

8.  Selective preservation of bone marrow mature recirculating but not marginal zone B cells in murine models of chronic inflammation.

Authors:  Elisabetta Traggiai; Anna Casati; Michela Frascoli; Simona Porcellini; Maurilio Ponzoni; Francesca Sanvito; Lin Leng; Richard Bucala; Lorenzo Moretta; Fabio Grassi
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

9.  Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions.

Authors:  Gregg V Crichlow; Jodi B Lubetsky; Lin Leng; Richard Bucala; Elias J Lolis
Journal:  Biochemistry       Date:  2009-01-13       Impact factor: 3.162

10.  Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening.

Authors:  Zoe Cournia; Lin Leng; Sunilkumar Gandavadi; Xin Du; Richard Bucala; William L Jorgensen
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.